Yuhan's lung cancer drug Leclaza cleared as Korea's 31st novel therapy
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The approval marks the country’s 31st home-made novel therapy that was achieved in three years after marketing approval of HK inno.N’s gastroesophageal reflux disease drug K-cab (Tegoprazan).
Lung cancer is a leading cause of death in Korea, and NSCLC is the most common lung cancer, with 30 to 40 percent of NSCLC patients with positive epithelial growth factor receptor (EGFR) mutation. For these patients, first- and second-generation targeted cancer therapies are standard of care but more than half of them experience treatment resistance at some point due to mutations, representing a highly unmet medical need.
Yuhan's Leclaza is a solution to address this resistance problem. It is known to have excellent efficacy even in the treatment of lung cancer that metastasizes to the brain as it can pass through the blood-brain barrier, according to the company.
Yuhan shares were trading up 1.11 percent at 72,900 won ($66.18) in morning trade on Tuesday.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Yuhan’s lung cancer drug Leclaza cleared as Korea’s 31st novel therapy - Pulse by Maeil Business News Korea
- Samsung heir’s jail sentence disrupts management succession plans - Pulse by Maeil Business News Korea
- Fubon Hyundai Life plans $551 mn capital expansion ahead of new accounting rule - Pulse by Maeil Business News Korea
- Google, Facebook, Neflix must ensure network and service stability in Korea - Pulse by Maeil Business News Korea
- Samsung heir Lee returns to prison upon sentenced 2 and 1/2 years jail term - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 금융당국이 손보려는 농협중앙회...NH농협금융 지배구조 ‘복마전’ 왜?
- 대만 치어리더 한국스포츠 첫 진출…K리그 수원FC - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이